scholarly journals Analysis of TCR antagonism and molecular mimicry of an HLA-A*0201-restricted CTL epitope in primary biliary cirrhosis

Hepatology ◽  
2002 ◽  
Vol 36 (4) ◽  
pp. 918-926 ◽  
Author(s):  
Hiroto Kita ◽  
Shuji Matsumura ◽  
Xiao-Song He ◽  
Aftab A. Ansari ◽  
Zhe-Xiong Lian ◽  
...  
2003 ◽  
Vol 124 (7) ◽  
pp. 1915-1925 ◽  
Author(s):  
Shinji Shimoda ◽  
Minoru Nakamura ◽  
Hiromi Ishibashi ◽  
Akira Kawano ◽  
Takashi Kamihira ◽  
...  

Hepatology ◽  
2003 ◽  
Vol 38 ◽  
pp. 203-203
Author(s):  
C SELMI ◽  
D BALKWILL ◽  
P INVERNIZZI ◽  
A ANSARI ◽  
R COPPEL ◽  
...  

2010 ◽  
Vol 29 (6) ◽  
pp. 313-321 ◽  
Author(s):  
Teru Kumagi ◽  
Masanori Abe ◽  
Yoshiou Ikeda ◽  
Yoichi Hiasa

Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease of autoimmune etiology, characterized by injury of the intrahepatic bile ducts that may eventually lead to cirrhosis and liver failure. Evidence suggests cardinal roles for both environmental factors and genetic susceptibility. Nevertheless, the absolute etiology of PBC is unclear, despite recent well-designed case-control studies that reported environmental risk factors, including infectious agents, for PBC. Of the reported infectious agents, some of them are not reproducible and remain controversial. However, infection is no doubt one of the major risks among the environmental factors. This is supported by the fact that infectious agents in autoimmune diseases express antigens resulting in molecular mimicry and xenobiotics that play a role in breaking tolerance. Taken together, recent findings from genome wide assays as well as novel animal models may enable us to better understand the mechanism of pathogenesis responsible for this disease.


1995 ◽  
Vol 181 (5) ◽  
pp. 1835-1845 ◽  
Author(s):  
S Shimoda ◽  
M Nakamura ◽  
H Ishibashi ◽  
K Hayashida ◽  
Y Niho

We established six T cell clones specific for pyruvate dehydrogenase complex (PDC)-E2 peptides from four different patients with primary biliary cirrhosis using 33 different peptides of 17-20 amino acid residues corresponding to human PDC-E2 as stimulating antigens. The minimal T cell epitopes of these six T cell clones were all mapped to the same region of the PDC-E2 peptide 163-176 (GDLLAEIETDKATI), which corresponds to the inner lipoyl domain of PDC-E2. The HLA restriction molecules for this epitope were all identified as HLA DRB4 0101. The common essential amino acids of this epitope for these T cell clones were E, D, and K at positions 170, 172, and 173, respectively; other crucial amino acids for this epitope differed in each T cell clone. In addition, the alanine-substituted peptides at positions 170 and 173, but not 172, inhibited the proliferation of all T cell clones induced by the original peptide of human PDC-E2 163-176, indicating that amino acid D at position 172 is a critical MHC-binding site for all T cell clones tested. Interestingly, all T cell clones reacted to PDC-E2 peptide 36-49 (GDLIAEVETDKATV), which corresponds to the outer lipoyl domain of human PDC-E2. Furthermore, one T cell clone cross-reacted with exogenous antigens such as Escherichia coli PDC-E2 peptide 31-44/134-147/235-248 (EQSLITVEGDKASM), which has an EXDK sequence. This is a definite demonstration of the presence of molecular mimicry at the T cell clonal level in human autoimmune diseases. It is also considered possible to design peptide-specific immunotherapy based on the findings of T cell autoepitopes in primary biliary cirrhosis.


Sign in / Sign up

Export Citation Format

Share Document